The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
It is incredibly annoying how these executives manipulate circumstances into their own favour, shandy.
Even more so when they have done so with our (lost?) hard-earned.
Can't see what else we can do but wait/hope for a decent H2 '23 and beyond to try and grab a bit back...
My reassurance is Viatris on board and most of the larger shareholders in at similar prices to myself (rough guess), which avoids, I hope a DNL style robbery, rather than (another) postulating yank with tailored interviews as you correctly state.
On the other hand, playing devil's advocate, quite a few of them have large amounts @ silly pence prices so it could be a closer run thing, but hopefully not enough to get the required %.
Good luck all fellow long sufferers - into my 8th year, as it's life, I may get out in 4 more ....
Even better for YU, as they have absolutely nothing to do with it.
It's the big boys throwing their weight around (again).
If it was me, I'd switch to a smaller, more caring Company to teach them a lesson ....
'A law firm representing several hundred small firms has written to British Gas, E.ON, SSE and Opus alleging that they inflated customers’ bills by billions of pounds by making payments to brokers without their customers’ knowledge.'
I didn't mean I expected £2, rather that I remember it being that after FDA was granted...
However, since the dilutions after that, I'd be saying maybe £1+ takeout?
This is taking into account the rights to Accrufer world wide as well as US. We know the market is always looking ahead, so I don't think that price is too far fetched. If the previous CEO's hadn't made such a pig's ear of it all, we'd be saying that same price was a joke!!
Good luck to all holders.
MC £19M !! Crazy. FDA approved and selling.
SNG - 1 drug, unapproved. Not looking likely to get any in the near future either, let alone sell it - MC £28M !!
The world has gone completely barmy.
Strong into close - GLA.
Unlike DNL, major shareholder's (bar 1) are in a lot higher, fortunately for us lowly pi's.
US taking off, world wide rights following behind.
It will take a bit more than 12p - I suggest the + being a minimum of 38p (and that's a bargain).
It will be the Anadin Extra of ID/A in years to come - more expensive because it is the best out there.
Interesting move though late on.
I was testing on IG and they wanted 6.39p for up to 100,000 shares - somebody paid it for 75,000.
They wanted 8p for any amount above! Hoping good news has dripped out.
GLA.
The first positive close for some considerable time.
Let's hope for a positive TU next week and the start of a revival.
GLA.
It's always the same when a share gets bashed - 'Opportunity Knocks' for the unscrupulous and selfish. You only have to look at how many times they have appeared on STX with reasonable debate in the past for this to be confirmed. Not great, but it is what it is.
Moving forwards, they are steadily filling the necessary vacancies for a Q2 sales force of 100. I'd suggest that thereafter would be a good time to start doing the math!
GLA/ATB.
Agree with all that has been said.
I'm surprised they don't seem too bothered about the continual decline here, despite the tech looking sound and in high demand imho.
Been in for years, miles down lol.
Hope 2023 is a better year for all the loyal LTH's.
ATB.
He's not in a hurry to get the TU out then.
They had 48 roles advertised - 34 reps and 14 managers positions.
I've just checked and 8 of the managers jobs look like they've been filled already. Took a few days!
Looks good for H1 and in particular H2 2023 onward.
China $11.4M follows on thereafter, late '23 or early '24.
Add in Norgine progress + Canada/S.Korea advancement.
All imho DYOR etc. Good luck all.